Haemonetics Corporation
General ticker "HAE" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $3.2B (TTM average)
Haemonetics Corporation follows the US Stock Market performance with the rate: 13.9%.
Estimated limits based on current volatility of 1.6%: low 63.53$, high 65.54$
Factors to consider:
- Total employees count: 3657 (+20.5%) as of 2024
- US accounted for 74.1% of revenue in the fiscal year ended 2024-03-30
- Top business risk factors: Cybersecurity threats, Market competition, Market decline, Customer dependency, Strategic risks and growth management
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-03-31 to 2026-03-31
- 2024-03-31 to 2025-03-31 estimated range: [64.37$, 96.37$]
- 2025-03-31 to 2026-03-31 estimated range: [64.90$, 97.16$]
Financial Metrics affecting the HAE estimates:
- Negative: with PPE of 20.1 at the end of fiscal year the price was high
- Positive: 7.67 < Operating profit margin, % of 12.60
- Positive: -0.01 < Industry operating cash flow per share per price (median), % of 0
- Positive: 42.68 < Shareholder equity ratio, % of 43.72 <= 64.29
- Positive: -14.22 < Investing cash flow per share per price, % of -7.93
- Positive: -9.07 < Industry operating profit margin (median), % of -7.44
- Positive: 0.01 < Operating cash flow per share per price, % of 4.47
Short-term HAE quotes
Long-term HAE plot with estimates
Financial data
| YTD | 2022-03-31 | 2023-03-31 | 2024-03-31 |
|---|---|---|---|
| Operating Revenue | $993.20MM | $1,168.66MM | $1,309.06MM |
| Operating Expenses | $912.45MM | $1,012.63MM | $1,144.17MM |
| Operating Income | $80.75MM | $156.03MM | $164.88MM |
| Non-Operating Income | $-17.12MM | $-14.63MM | $-13.02MM |
| Interest Expense | $17.12MM | $14.63MM | $13.02MM |
| R&D Expense | $55.20MM | $58.63MM | $63.03MM |
| Income(Loss) | $63.63MM | $141.40MM | $151.87MM |
| Taxes | $20.25MM | $26.00MM | $34.31MM |
| Profit(Loss)* | $43.38MM | $115.40MM | $117.56MM |
| Stockholders Equity | $749.42MM | $818.00MM | $959.96MM |
| Inventory | $293.03MM | $259.38MM | $317.20MM |
| Assets | $1,859.73MM | $1,934.83MM | $2,195.59MM |
| Operating Cash Flow | $172.26MM | $273.06MM | $181.75MM |
| Capital expenditure | $96.51MM | $110.19MM | $66.30MM |
| Investing Cash Flow | $-86.34MM | $-143.79MM | $-322.39MM |
| Financing Cash Flow | $-15.75MM | $-100.36MM | $38.16MM |
| Earnings Per Share** | $0.85 | $2.27 | $2.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.